The endogenous estradiol metabolite 2-methoxyestradiol reduces atherosclerotic lesion formation in female apolipoprotein E-deficient mice

Endocrinology

Volumn 148, Issue 9, 2007, Pages 4128-4132

  Bourghardt, Johan ^a   Bergström, Göran ^a   Krettek, Alexandra ^a   Sjöberg, Sara ^a   Borén, Jan ^a   Tivesten, Åsa ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; APOLIPOPROTEIN E; ESTRADIOL; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DRUG INHIBITION; FEMALE; HYPERLIPOPROTEINEMIA TYPE 3; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UTERUS WEIGHT; WEIGHT GAIN;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BODY WEIGHT; ESTRADIOL; FEMALE; MICE; MICE, KNOCKOUT; ORGAN SIZE; TUBULIN MODULATORS; WEIGHT GAIN;

EID: 34548108398     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0259     Document Type: Article

References (28)

1. Hodgin JB, Maeda N 2002 Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 143:4495-4501
2. Liu PY, Death AK, Handelsman DJ 2003 Androgens and cardiovascular disease. Endocr Rev 24:313-340
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
4. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J 2006 Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113:2425-2434
5. Barrett-Connor E 2003 Clinical review 162: cardiovascular endocrinology 3: an epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab 88:4031-4042
6. Dubey RK, Imthurn B, Zacharia LC, Jackson EK 2004 Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 44:789-795
7. Zhu BT, Conney AH 1998 Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1-27
8. Dubey RK, Tofovic SP, Jackson EK 2004 Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther 308:403-409
9. Mooberry SL 2003 Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Update 6:355-361
10. Dantas AP, Sandberg K 2006 Does 2-methoxyestradiol represent the new and improved hormone replacement therapy for atherosclerosis? Circ Res 99:234-237
11. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK 2006 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res 99:266-274
12. Tofovic SP, Salah EM, Dubey RK, Melhem MF, Jackson EK 2005 Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol 46:25-35
13. Tofovic SP, Salah EM, Mady HH, Jackson EK, Melhem MF 2005 Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 46:430-437
14. Markides CS, Roy D, Liehr JG 1998 Concentration dependence of prooxidant and antioxidant properties of catecholestrogens. Arch Biochem Biophys 360:105-112
15. Purcell-Huynh DA, Farese Jr RV, Johnson DF, Flynn LM, Pierotti V, Newland DL, Linton MF, Sanan DA, Young SG 1995 Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 95:2246-2257
16. Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G 2006 2-Methoxyestradiolmediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol 45:358-367
17. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N 2001 Estrogen receptor α is a major mediator of 17β-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest 107:333-340
18. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS 2002 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors α and β. Cancer Res 62:3691-3697
19. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M 2001 Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 37:640-644
20. Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG, Barchiesi F, Dubey RK 2003 Methoxyestradiols mediate the antimitogenic effects of 17β-estradiol: direct evidence from catechol-O- methyltransferase-knockout mice. Circulation 108:2974-2978
21. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
22. Sibonga JD, Lotinun S, Evans GL, Pribluda VS, Green SJ, Turner RT 2003 Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 144:785-792
23. Seeger H, Mueck AO, Lippert TH 1999 Effect of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sci 65:PL167-PL170
24. Madamanchi NR, Vendrov A, Runge MS 2005 Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25:29-38
25. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA 2004 COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306:1954-1957
26. Barchiesi F, Jackson EK, Gillespie DG, Zacharia LC, Fingerle J, Dubey RK 2002 Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension 39:874-879
27. Liu D, Bachmann KA 1998 An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats. J Pharmacol Exp Ther 286:561-568
28. Elhage R, Arnal JF, Pieraggi MT, Duverger N, Fievet C, Faye JC, Bayard F 1997 17β-Estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 17:2679-2684